Implements the Omega interaction disproportionality measure
of Noren et al. (2008)
The goal of PVomega is to detect drug-drug-event statistical patterns supporting hypotheses generation on drug-drug interactions in databases of adverse event reports.
You can install the development version of PVomega like so:
install.packages("pak")
pak::pak("Uppsala-Monitoring-Centre/PVomega")
and load the library like so:
library("PVomega")
Omega (Noren et al. 2008) is a disproportionality measure for drug-drug-event combination. It compares the observed number of reports listing two drugs and an adverse event with the number expected if the two drugs did not interact.
“No interaction” is defined by an additive model: the reporting rate of the event under both drugs is the background reporting rate plus the contribution attributable to each drug. This is the key difference from logistic regression, whose interaction term assumes multiplicative effects of separate drugs and misses well-established interactions such as cerivastatin with gemfibrozil.
The steps are:
f00, f10, f01, f11.g11, from f00,
f10 and f01 only (eq. 16 of the paper).E111 = g11 * n11..omega = log2((n111 + 0.5) / (E111 + 0.5))
and its Gamma credibility interval.A potential interaction is highlighted when omega_lower is above 0.
omega_from_counts() works with any data source. The example below is
the first case study of the paper: delayed bleeding with itraconazole
and oral contraceptives.
res <- omega_from_counts(
n111 = 10, n11. = 23, n1.1 = 10, n.11 = 19,
n1.. = 39, n.1. = 1489, n..1 = 39, n... = 5503
)
res[, .(f00, f10, f01, f11, g11, E111, omega, omega_lower, omega_upper)]
#> f00 f10 f01 f11 g11 E111 omega
#> <num> <num> <num> <num> <num> <num> <num>
#> 1: 0.005002501 0 0.006139154 0.4347826 0.006139154 0.1412005 4.03347
#> omega_lower omega_upper
#> <num> <num>
#> 1: 3.003327 4.790041
With the DiAna data and package imported, the DiAna function
omega_analysis() computes all counts and returns one row per
drug1-drug2-event combination (script not run).
library(DiAna)
FAERS_version <- "24Q4"
import("DEMO")
import("DRUG")
import("REAC")
res <- omega_analysis(
drug1_selected = "miconazole",
drug2_selected = "warfarin",
reac_selected = c("international normalised ratio increased", "haemorrhage"),
restriction = Demo[!RB_duplicates_only_susp]$primaryid
)
res
Groups of terms can be collapsed with lists, as in DiAna:
omega_analysis(
drug1_selected = list(statins = c("simvastatin", "atorvastatin")),
drug2_selected = "clarithromycin",
reac_selected = list(muscle = c("rhabdomyolysis", "myopathy", "myalgia"))
)
Three choices for the parameters in the DiAna function
omega_analysis() change the counts, and should be stated in any
publication:
drug_roles). By default only primary suspect,
secondary suspect and interacting drugs count as exposure, as at
Uppsala Monitoring Centre. Reports where a drug is only concomitant
fall into the background stratum.restriction). FAERS contains duplicate reports.
Pass the primary IDs retained by one of DiAna’s deduplication
algorithms.n... is the number of distinct
reports in temp_reac (within restriction). Every count refers to
this population.As recommended in the original paper, do not read Omega in isolation.
The columns f00, f10, f01 and f11 show why a combination was
highlighted. For example, a large f10 means D1 alone already explains
much of the reporting.
Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Research Report. 2007;2007:6. Mathematical Statistics, Stockholm University.
Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008;27(16):3057-70.
Hult S, Sartori D, Bergvall T, et al. A feasibility study of drug-drug interaction signal detection in regular pharmacovigilance. Drug Saf. 2020;43:775-85.